The award, which is sponsored by Zoetis, was given online this year at an event hosted by sports television presenter Mark Durden-Smith and Chloe Ryan, the editor of Poultry Business.
William was brought up on a sheep farm in Nottinghamshire and as a youngster bred rare breed poultry, selling eggs to local people in the village. He graduated at Nottingham University, did a poultry internship with a practice in the North West and worked there initially. Four years ago, he set up his own practice Avivets, at High Legh in Cheshire, dedicated to the poultry and game bird sector. He guest lectures at the Universities of Nottingham and Surrey and is an official veterinarian for avian exports. He sits on the RSPCA’s technical standards advisory board and was recently appointed veterinary advisor for the NFU poultry board.
Chloe Ryan said he had impressed the judges ‘with his enthusiasm for poultry veterinary knowledge and entrepreneurship. He has shown an excellent level of dedication, enriching his experience and qualifications through continuous professional development to farms and flocks as evidenced by glowing praise from a long list of clients.’
Lucy Berriman, Zoetis UK poultry national account manager, said: “Zoetis is proud to be sponsors of this new award for the industry’s poultry vets.
"It gives hardworking individuals the chance to shine and illustrate their commitment to the poultry industry. Congratulations to Will for this fabulous achievement, and well done to the other two finalists."
The other finalists were Helena Brewer, who joined the Poultry Health Services team at Sheriff Hutton, near York, after studying at the Royal (Dick) School at Edinburgh and the Royal Veterinary College, and Henry Lamb, who has worked at Crowshall Veterinary Services in Norfolk since graduating at the Royal Veterinary College.
Vetoquinol UK Limited has launched Ceftiocyl: a ready-to-use formulation containing 50mg/ml ceftiofur for use in cattle and pigs.
In cattle, Ceftiocyl can be used for the treatment of respiratory disease, acute interdigital necrobacillosis and acute post-partum metritis. In pigs, Ceftiocyl is licensed for the treatment of respiratory disease. Ceftiocyl has the added benefit of traceability stickers which are attached to each vial making it easier and quicker to record and monitor on-farm usage.
Susan Mitchell, Large Animal Product Manager at Vetoquinol UK Ltd said, 'We are delighted to be expanding our large animal anti infective range offering. Marbocyl 10% has been used for acute mastitis in the dairy sector for many years, the addition of Ceftiocyl to our portfolio enables us to provide a cost-effective treatment for both metritis and lameness.'
1. Willshire, J.A. & Bell, N, J. (2009) An economic review of cattle lameness. Cattle Practice 17, 136-141.
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Reference
The company provides official veterinarians, meat hygiene inspectors and other technical staff to the regulatory compliance sector, and its other clients include Defra, APHA, the Food Standards Agency, DAERA, AHDB, and several private organisations across the UK.
Hallmark says discussions have been ongoing with FSS since mid-2018, since when the company has faced increasing challenges in recruiting and retaining veterinary staff, as a result of eroding salary values and the weakening pound post-Brexit.
David Peace, Chairman of HallMark Meat Hygiene said: "The position we presented to FSS set out HallMark’s case for a substantial increase in funding to apply entirely to frontline veterinary salaries.
"Starting salaries for veterinary staff working with HallMark in this sector had altered very little during the past twenty years. As a responsible employer and trading partner, and with inflation and a weaker pound severely testing real pay levels, HallMark felt it necessary to address those issues robustly and directly to ensure staff are properly compensated and, as a result, that services are stabilised for the benefit of the Scottish meat industry."
"We’re naturally disappointed to part company with a valued customer such as FSS. By mutual agreement last year, we submitted a business case setting out what we believe is necessary to stabilise and maintain service delivery into the future. Ultimately, FSS decided not to accept that business case, and we consequently requested to be released from our contract with them.”
HallMark says it will continue to provide veterinary and technical services to government departments across the UK. Indeed, only last year HallMark’s parent company acquired MLCLS (Meat and Livestock Commercial Services Limited), the leading independent carcase classification business, originally owned by AHDB. HallMark is also an equal partner in its joint venture company, Probita Solutions Limited, which recruits and deploys vets in support of veterinary practices involved in TB testing activities.
The company also says it will continue to bid for major meat sector tenders in the future.
Mr Peace added: "This news should absolutely not be interpreted as a HallMark withdrawal from meat industry official controls. We will continue to offer the same diligence and dedication to welfare and hygiene standards, wherever opportunities arise, and it will be our mission to offer to government the most efficient and professional compliance services possible, optimising the cost of compliance delivery."
The award recognises an exceptional farm vet who has been working in the dairy industry for three to five years and contributed significantly to the health and wellbeing of the herds under their care.
Rob joined LLM Vets after graduating from Cambridge University Vet School in 2017. He has particular interests in lameness, calf rearing and housing design. He said: “Since joining LLM, I have thrown myself into all aspects of the practice – from the Agricultural Show season to driving LLM’s BVD eradication efforts and revamping our herd health planning scheme. My role in practice management is also growing. I currently oversee work for the Johnes CHeCS programme and help to guide our industry-leading team of VetTechs."
He added: “I find the interaction between dairy cattle and their environment fascinating and, following some specialist training I undertook with the Dairyland Initiative in Wisconsin, I’ve been helping our farmers to make major changes to their cow and calf housing, particularly by improving ventilation.”
CREAM judge Rob Drysdale said: “Rob Hall really stood out because of the additional services he’s trying to offer, for instance, getting involved in the Stamping Out BVD campaign and utilising his specialist skills in calf housing ventilation to increase welfare standards. Rob would be a real asset to any farm or vet business.”
Charlotte Read, Key Account Manager – Farm, at Krka, added: “Newly qualified vets represent the future of this exciting and rapidly-evolving profession so we are particularly delighted to have the opportunity to highlight their achievements. Krka is proud to support the UK’s dairy sector and we congratulate both Rob and Rupert on the huge contribution they are making to their clients and their practices.”
A new infographic and educational webinar are now available to share on social media, to increase farmer awareness and provide best practice guidance.
The infographic and webinar explain how vaccination is considered best practice for control of the disease, giving better disease control whilst ensuring responsible use of antibiotics.
Independent sheep veterinary consultant Dr Fiona Lovatt, who leads the cross-industry Sheep Antibiotic Guardian Group, said: "Despite EAE being responsible for over 35% of all abortion diagnoses, only one million of the 3.5 million replacement ewes in the national flock each year are vaccinated against EAE. Any sheep farmer that either buys in ewes for replacements or has close neighbours that also lamb sheep, risks bringing enzootic abortion into their flock.
"Once the disease infects an unvaccinated flock, some ewes are ‘programmed’ to abort at their next lambing, leaving no choice but to put remedial measures in place – usually including both vaccination and antibiotic treatment.
"This means EAE is a disease that, once in a flock, carries high costs both financially and emotionally in terms of lamb losses and farmer stress. Hence it is important that flocks receive appropriate vaccination at least four weeks before ewes go to the ram and avoid the inappropriate use of antibiotics closer to lambing."
Fiona points out that a single dose of EAE vaccine costs about £2.40 and is an investment that effectively lasts the ewe for her lifetime in the flock, protecting against losses. In contrast, abortion or stillbirth – which accounts for around a quarter of all lamb losses each year – costs over £25 for every single lost lamb.
Fiona added: "Every injection of antibiotics also costs an additional £1. But is just a ‘sticking plaster’ with short-lasting effectiveness in terms of disease control but long-lasting damage in terms of mounting resistance."
Ceva says it will continue to work closely with veterinary practices to secure stock of Cevac Chlamydia vaccine to ensure farmers can purchase and use the vaccine at the right time. Ceva also provides subsidised blood sampling for diagnostic purposes.
For further information, call Ceva Animal Health on 01494 781510 or email cevauk@ceva.com.
Photo: Mike Benjamin
Hysolv says the vaccine, which was developed by IDT Biologika, has been used successfully in Germany, where 1.7 million doses have been prescribed. The company says field trials have shown that vaccination not only protected against clinical signs of influenza but also resulted in improvements in reproduction and piglet performance.
Two 1 ml doses of the inactivated vaccine can be injected intramuscularly three weeks apart to pigs from 56 days old, providing immunisation to the majority of animals within seven days.
Hysolv director, Geoff Hooper said: "Swine flu can be devastating to a herd and this vaccine will broaden protection, particularly when used with our existing vaccine Respiporc FLU3, which we are strongly advising."
Respiporc FLU3 protects against three other strains of swine flu (H1N1, H1N2 and H3N2). Hysolv says that when used together, the two vaccines protect pigs against the most relevant strains in the British Isles.
Geoff added: "There have been several flu pandemics throughout the years – the latest in 2009. It is not possible to predict the emergence of a pandemic strain accurately but this vaccine combined with Respiporc FLU3 will greatly decrease the chance of pigs becoming infected."
Vetoquinol has announced the introduction of Melovem to the UK market. Melovem is a new injectable preparation containing 5mg/ml meloxicam which is licensed for use in pigs and young cattle.
According to the company, meloxicam is the most widely used veterinary non steroidal anti-inflammatory injection in the UK. Presented in 100ml bottles, with a lower dose formulation, Melovem can be a cost-effective NSAID solution to leave on-farm.
Mark Leddy from Vetoquinol said: "We are pleased to be the distributors of Melovem in the UK. Melovem provides vets and farmers with a new, cost-effective meloxicam injection that is suitable for on-farm use."
Contact your Vetoquinol representative for more information on Melovem, or call Vetoquinol on 0800 1608197.
The company says Taurador Pour-on provides a stress-free, easy to use treatment, with persistent activity against a large number of cattle parasites, therefore ensuring effective coverage over long periods of the grazing season.
Matthew Swanborough BVSc MRCVS, Veterinary Advisor for Norbrook, said: "The farming industry will be aware that heavy worm burdens can significantly affect the health and productivity of cattle, potentially as much as £100 per head of cattle. We cannot simply ignore these parasites but we must tackle them responsibly. A comprehensive worming strategy is a vital component of any animal health plan, which should be composed of management strategies and any necessary anthelmintic treatments."
Norbrook highlights the product's efficacy against the gutworms Osterstagia osterstagi, Cooperia oncophora and lungworm, Dictyocaulus viviparous, with persistent action against these parasites for 35 days, 28 days and 42 days respectively.
Doramectin, the active ingredient in Taurador, is an anthelmintic belonging to the macrocyclic lactones (3-ML) group, along with ivermectins. Norbrook says both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods.
Dr Leigh Sullivan, Norbrook Large Animal Product Manager, said: "Taurador is the company’s thirteenth new product introduction in the last four years and it is a significant addition to our portfolio. Internal parasites such as gutworms and lungworm can have a serious impact on animal health and welfare, as well as financial implications for farmers, so it is great to be able to provide another product to help reduce the economic impact of these parasites."
Taurador is available in three different pack sizes (1L; 2.5L and 5L) and an appropriate dosing applicator is also available.
The company says that CircoMax Myco offers the longest lasting combined protection on the EU market against PCV2 and M. hyopneumoniae pathogens. This reduces the PCV2 viral load in blood and lymphoid tissues, PCV2 fecal shedding, lymphoid tissue lesions associated with PCV2 infection, and lung lesions associated with M. hyopneumoniae infections.
Pig protection was demonstrated against porcine circovirus genotypes 2a, 2b and 2d and lasts for at least 23 weeks after vaccination in fattening pigs for both PCV2 and M. hyopneumoniae.
Monica Balasch, Director, Global Biologicals Development at Zoetis, said: "Porcine circovirus type 2 has demonstrated high mutation and recombination rates and is known to be rapidly evolving in Europe and worldwide. Commercial PCV2 vaccines have been efficacious in controlling the clinical disease, but there is a growing genetic gap between field viruses and vaccines. So far, all vaccines in Europe have been based on one single genotype, PCV2a, while today the most prevalent viruses found belong to other genotypes: PCV2b and especially PCV2d.
“We believe that there is a need for new vaccines, like CircoMax Myco which includes two PCV2 genotypes for a broader coverage. We found excellent results showing reduction of body weight gain losses in field trials in the EU. This innovative one-dose vaccine is a new tool for veterinarians and producers that may improve their PCV2 and M. hyopneumoniae control programs, especially in the face of multi-genotype PCV2 infections.”
Alvaro Aldaz, Director, Global Commercial Development, Swine, Zoetis, said: "For many years, intensive vaccination has contributed to selective pressure and emergence of new PCV2 genotypes. European pig farms are often infected with more than one genotype and subclinical disease is frequent. Commercial vaccines are all based on PCV2a genotype while CircoMax Myco is the first vaccine that includes two PCV2 genotypes (a & b), and the inventive M. hyopneumoniae purified fraction. It is formulated with MetaStim for active immunization, resulting in 23 weeks of protection against these threats."
CircoMax Myco contains inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (ORF2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b ORF2 protein and inactivated Mycoplasma hyopneumoniae, strain P-5722-3.
MSD Animal Health has announced a new claim for Bovilis BVD and Bovilis IBR Marker Live vaccines which means they can be mixed and administered in a single syringe.
MSD says the new mixing claim will offer significant advantages in herd health planning when controlling two of the more important infectious diseases in cattle.
Bovine Viral Diarrhoea (BVD) and Infectious Bovine Rhinotracheitis (IBR) remain major threats to cattle health and productivity. Vaccinations are commonly given at housing and/or turnout, which are both busy times for veterinary surgeons and on the farm in the herd health planning calendar.
The mixed vaccines are suitable only for booster vaccinations of animals from 15 months of age previously vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD. The mixed vaccine needs to be used within three hours.
MSD says the mixing procedure is clear and easy, but there is an instructional video here: http://www.msd-animal-health.co.uk/Mixing_bovilis_BVD_Bovilis_IBR-Marker_Live.aspx
Hysolv Animal Health has announced the launch of Salmovac 440, a new live salmonella vaccine for poultry which the company claims gives earlier, stronger and longer-lasting immunity than other salmonella vaccines.
The vaccine is given orally through the water supply in a three-dose regime that protects against Salmonella Enteritidis (SE) and Salmonella Typhimurium (ST). It also protects against other SE strains and the newly-emerging monophasic Salmonella Typhimurium strains.
Hysolv says the advantage for farmers is that the vaccine strain is robust and can survive in more hostile conditions. It therefore remains effective where the water delivery system is less than ideal.
The first dose is administered from Day 1 followed by a second dose at six weeks and a third as early as 11 weeks. Salmovac 440 protects chicks after six days and remains effective for up to 63 weeks after the third vaccination, providing an extra four weeks of protection.
Hysolv says another important benefit to egg producers is that the earlier final vaccination at 11 weeks means that the birds can be moved into the laying house as early as 16 weeks old if required — a significant management advantage on some farms.
During the development of the vaccine it was found that the third live vaccination tended to ‘shut down’ any prolonged shedding of the vaccine strain. This, coupled with the earlier vaccination at 11 weeks, helps solve the issue of the vaccine strain being found at transfer to the layer house. Dr Daniel Windhorst, salmonella vaccine specialist with IDT Biologika, said: "If any should be found, the new PCR (Polymerase Chain Reaction) test shrinks the testing time to just two to three hours."
Daniel added: "Although the UK has one of the lowest percentages of salmonella in its flocks, almost one-third of cases were of S Typhimurium. In most continental countries the percentage is much higher, so the extra cover provided by this vaccine is important."
Salmovac 440 has been approved for use by the British Egg Industry Council, which administers the Lion Code.
The company says that the composition and dosage of the new product has been optimised for maximum efficacy 1, 2. It offers three-five days on-label treatment options and does not need to be stored in a fridge.
According to Boehringer, the 600mg dose results in a concentration well above MICs for Strep. uberis and Staph. aureus for 24 hours, even after milking, which means it needs to be administered once a day1. In addition, its formulation enables optimum distribution of penicillin throughout the udder2.
Kath Aplin veterinary adviser at Boehringer Ingelheim said: "Traditionally, in the UK, we have favoured broad spectrum mastitis therapy as our first line approach, however in many other European countries, including The Netherlands, Belgium, Sweden and Denmark, penicillin is the treatment of choice.
"For farms with a mixed or unknown mastitis pattern, the traditional broad spectrum approach to mastitis therapy makes sense. However, many vets now have a good knowledge of common mastitis pathogens on clients’ farms and, for those where gram +ve pathogens predominate, penicillin as a first line treatment is well worth considering."
In a field trial assessing the prevalence of mastitis-causing pathogens and clinical cure rates after treatment with Ubropen3, mild and moderate cases of mastitis were treated for three to five days, with the causal pathogen being unknown at the time of treatment.
Kath said: “In 80% of cases of grade one or two clinical mastitis, the causative pathogen was found to be gram +ve and, following treatment with Ubropen, the overall clinical cure rate was 81%".
Ubropen is now available from the usual veterinary wholesalers in boxes of 20 tubes.
References:
1,219 farmers took part in the survey: 44% beef and 56% dairy. For the first time, the survey was also tailored for the regions. 488 responses came from famers in England, 380 from Scotland, 164 from Wales and 237 from Northern Ireland.
Boehringer Ingelheim’s Matt Yarnall, who led the project, said: "Headline findings are that farmers have regrets about holding onto persistently infected animals (PIs) which, at the end of the day, no-one should be doing.
"The financial benefit of being free of BVD was estimated as being over £90 per cow per year and when asked what impact BVD has had on their herd, the majority of producers highlighted poor fertility and high levels of disease in the herd.”
Boehringer says the identification of persistently infected animals (PIs) through tag and testing, supported by improved herd biosecurity and vaccination, could cost as little as £10 per cow per year, representing a significant return on investment for a disease with severe financial impact.
Matt said: "Herd biosecurity is also hugely variable. The most commonly selected response was operating a closed herd but, as most practitioners will know, the definition of a true closed herd and the real-life execution of that can be two very different things."
Highlighting one of the other major challenges for producers in cattle-dense areas, results from Scotland that showed that 51% of farmers with neighbouring cattle are worried about their neighbours' BVD status.
Matt said: "Perhaps the most alarming finding was the lack of awareness of the intricacies of some BVD vaccination courses, especially around when they need to be restarted, in order to achieve the protection needed."
2017 survey data from last year showed that 71% of producers were failing to achieve adequate protection when using a BVD vaccine that requires a booster six months after the primary course.
Boehringer says the results showed this is mostly down to not properly understanding the exact nature of the timings for the two-dose primary course, dates of service and calving and then the booster date.
Matt added: "For any practitioner advising clients, the 2018 finding that a shocking 85% haven’t restarted a vaccination course when the majority should have done, should ideally serve as a clear call to action."
For more information about the findings of the National BVD Survey, email bvdzero.uk@boehringer-ingelheim.com.
The webinar, which will be streamed live at 8pm on Wednesday 20th November and will be available to watch for six months thereafter, is being presented by James Husband, an RCVS Specialist in cattle health & production.
Topics will include oxidative stress, its impact on cattle performance and the role of trace minerals in immunity and cattle health. The webinar will also cover the current complexities of oral supplementation including absorption and mineral antagonism, along with offering information about the latest innovation to boost trace mineral availability during high demand periods in the production and breeding life cycle.
To register for the webinar, visit: https://www.thewebinarvet.com/pages/register-free-role-trace-minerals-cattle-health-performance-new-veterinary-approach-boost-trace-mineral-availability/
All vets who view the webinar, either live or as a recording on the website, will be able to download a CPD certificate.
Bovilis Rotavec Corona is used for the active immunisation of pregnant cows and heifers, 12-3 weeks pre-calving, to raise antibodies against rotavirus, coronavirus and E. coli F5 (K99). Calves gain protection by drinking the fortified colostrum from their vaccinated mothers.
The company says the new license indication will mean greater usage flexibility for UK cattle producers focusing on immunity-led prevention of infectious calf scours.
MSD ruminant veterinary adviser Dr Kat Baxter-Smith said: "On the old license, this vaccine needed to be used within eight hours of opening, so this will be a significant benefit-led change for suckler beef and dairy producers.
"For all-year-round calving dairy herds, for example – that may want to vaccinate successive pregnant dams on different days – it will make an opened bottle of vaccine last much longer. Those running batch calving herds with a long calving period should also benefit. We hope this will help reduce unnecessary wastage of the vaccine on farm and save farmers money.”
MSD says it will still be crucial to store the vaccine properly – upright and refrigerated (at 2-8°C) before and after broaching, and after first use. A broached vial will be able to be used once more during the next 28 days after the first vaccination event and then discarded. Vaccination equipment such as needles and syringes should be sterilized. Use of a multi-dose syringe to minimise vaccine contamination and excessive broaching is recommended.
The vaccine vials should still be shaken well before use. The injection should be made through an area of clean, dry skin with precautions taken against contamination.
The product was one of eight NSAIDS that had been suspended following a European ruling that an excipient, diethanolamine, may pose a risk to human health.
Allevinix is licensed for both intravenous (I/V) and intramuscular (I/M) administration over one to three days in cattle. It has a dose rate of 4ml per 100kg liveweight in cattle, and milk withdrawal times of 24 hours after I/V injection and 36 hours after I/M injection.
Ceva says Allevinix reaches peak plasma levels (CMax) approximately 30 minutes following I/M injection. It is available in 100ml and 250ml vials.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: "Allevinix is the only flunixin licensed for both intramuscular and intravenous administration in cattle and provides both vets and farmers with a cost-effective, fast-acting and versatile NSAID that is a useful addition to the range of NSAID options available."
For more information, contact your Ceva account manager, email cevauk@ceva.com or call the ruminant marketing department at Ceva on 01494 781510.
Being an intranasal vaccine, Bovalto Respi IN triggers mucosal immunity in the nasal passages and throat area. It can be delivered from 10 days of age without the need for a booster and provides immunity for 12 weeks, from 10 days after vaccination.
Boehringer says it has also been shown to be effective in the face of MDA (maternally derived antibodies).
The new bottle now has a wider neck, which apparently makes for a better fit with the accompanying Respisafe applicator and nozzle.
Brand manager Matt Yarnall said: "The Respisafe applicator ensures that vaccination is a comfortable process for both farmer and calf and the improved fit will make the job even easier.
"With an intranasal vaccine, it is important that the vaccine droplets coat the mucosa of the nasal passages, where they can begin to work. If they are too big, then the vaccine can run out of the nose, and if too small then the droplets are carried into the lungs and are wasted. The Respisafe system ensures that the optimum size of droplet is administered to the right place in an efficient and easy way.”
Bovalto Respi Intranasal protects against the two main respiratory viruses – RSV and PI3, and during its development it was tested against current strains, that are associated with causing disease in cattle1.
Stock of the new bottles will start to enter circulation with vets from mid-July, with an expectation that the existing version will still be in circulation until early in the new year.
The company says this means that using Solacyl as an alternative to antibiotics could reduce overall antibiotic use by 4.4 tonnes a year.
The research was carried out by dairy veterinary consultant Owen Atkinson BVSc DHCP MRCVS, an RCVS recognised specialist in cattle health and production, at three English calf rearing units between November 2017 and May 2018. It involved four groups of beef calves from different dairy farms.
The 258 calves were given Solacyl (sodium salicylate) in-feed on the five days immediately upon arrival at the units (a high-risk period for animals to contract bovine respiratory disease).
According to Dechra, the use of Solacyl resulted in a reduction in antibiotic use of between 16% and 73% (based on doses), depending on the farm. Across all groups, the reduction was 43%.
Dechra says that neither the health of the calves nor the profitability of the rearing operations were compromised.
Owen Atkinson said: "I was involved in analysing the data and the data showed that there was no significant difference in growth rates or in mortality or in days to reach a target weight in the calves that had Solacyl, compared to previous batches of calves that had followed a prophylactic antibiotic protocol.
"I think this is an ideal protocol for those farmers who are competent, who are able to spot early pneumonia symptoms and are prepared to perhaps treat a slightly higher proportion of calves than they would otherwise have treated. They can now do that with higher confidence that their results should be as good as if they had used prophylactic antibiotics."
Dechra Farm Animal Veterinary Adviser Alana McGlade BVmedsci (hons) BVM BVS MRCVS added: "Sodium salicylate has the same fever-controlling, pain-managing and inflammation-reducing benefits in livestock as aspirin can have in humans.
"It can be administered conveniently to groups of animals, which means it can be given prior to known stress points in animals’ lives. This can be continued through and after those events, providing a welfare benefit and reducing the risk of a loss of appetite and its resulting effects.
"Solacyl can be administered without the supervision of a vet and that makes it a cost-effective and practical solution for farmers that can lead to a notable reduction in routine antibiotic use whilst protecting the welfare of a herd."
Dechra has now published a white paper which you can download here: "Enhancing welfare and combating antimicrobial resistance while maintaining productivity on calf units".
The results of the research will be presented at the BCVA Congress in October 2018.
Tulaven is licensed for the treatment and metaphylaxis of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis.
Tulaven can also be used to treat Infectious Bovine Keratoconjunctivitis (IBK) associated with Moraxella bovis as well as Porcine Respiratory Disease Complex (PRDC) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.
Tulaven is also is licensed to treat the early stages of infectious pododermatitis (foot rot) in sheep associated with virulent Dichelobacter nodosus.
Ceva highlights that Tulaven is the only tulathromycin available in CLAS (Ceva Layered Anti Shatter) vials1, which have less impact on the environment2, are easier to handle3 and transport4, and are preferred by farmers5.
Cuneyt Seckin, Managing Director of Ceva Animal Health, said: “Ceva has been developing its expertise in the treatment of BRD for many years, with a wide range of treatment options and autogenous vaccines available for vets. The launch of Tulaven is the next addition to this range, enabling us to offer even more support to vets and farmers.”
For further information, contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
References
This only affects batch number C967336A, expires before 07/2020. Any other batches of Tylan 200 Injection are not affected and may continue to be distributed.
Elanco is contacting wholesale dealers and veterinary surgeons to examine inventory immediately and quarantine products subject to this recall.
For further information regarding the recall, please contact Ms Victoria Haslingden 01256 779519 or email elanco_orders@lilly.com
Vetoquinol UK has launched Sodium Salicyl 80%, a water soluble, non-steroidal anti-inflammatory drug (NSAID).
Sodium Salicyl 80% contains 800mg of sodium salicylate and is indicated for supportive treatment of pyrexia in acute respiratory disease in calves (of at least two weeks of age). In pigs, Sodium Salicyl 80% is indicated for the treatment of inflammation, in combination with concurrent antibiotic therapy. Vetoquinol says that unlike acetylsalicylic acid (conventional aspirin) which is poorly soluble in water, sodium salicylate is highly water soluble (1 g/ml water), even in the hard water commonly encountered in the UK which makes it ideal for group therapy in any herd.
Sodium Salicyl 80% can be administered orally through the milk replacer or drinking water. Orally administered salicylates are absorbed rapidly and make it easier to treat groups of pigs and calves suffering from stress.
Vetoquinol says it's well known that any focus of pain or discomfort is likely to reduce an animals' feed and water intake, enough to reduce performance and potentially increase the need for the use of antibiotics. NSAID's are ideal for use in times of stress, for example after weaning where they have the ability to reduce inflammation, provide analgesia and reduce pyrexia. Unlike corticosteroids, NSAID's relieve pain and inflammation without the immunosuppressive and metabolic side effects. Stress is a known cause for an acute phase response (inflammation) and viral and bacterial infections are common in this vulnerable period.
Susan Mitchell, Large Animal Product Manager at Vetoquinol said: 'We are delighted to be expanding our large animal range with Sodium Salicyl 80%. We are now able to offer vets and producers a solution for both individual and group situations where an NSAID is required"
For the study1, 158 cows presented with active DD (M1, M2 or M4.1 stage) and were randomly allocated to either the control or the treatment group.
All cows were treated with a topical application of oxytetracycline spray.
The treatment group also received an intramuscular injection of Ketofen 10% solution for injection (ketoprofen 3mg/kg).
Cows were mobility scored just before they were treated and then again one week later.
The results indicated that animals in the control group were 2.57 times more likely to be lame at the second evaluation compared to those that received Ketofen, however cows that were lame in the control group prior to treatment and did not receive Ketofen were over 20 times more likely to remain lame a week post-treatment compared to cows that did receive Ketofen.
The same study all showed a milk yield benefit overall; treated cows produced 2.98 kg more milk than control cows (T = 45.35 C = 42.37, p<0.01).
When only lame fresh cows were considered, there was a 10.49kg increase in milk yield (T = 58.38 C = 47.89 p<0.05).
Nick Bell MA, VetMB, PhD, PGCert Vet Ed, FHEA, DipECAWBM(AWSEL), MRCVS, veterinary surgeon and director of Herd Health Consultancy, said: “We’ve widely recognised the importance of NSAIDs for treating claw lesions, which are primarily inflammatory conditions, but this study is the first real insight into how important NSAIDs are for any lesion, including digital dermatitis, particularly if the cow is showing signs of lameness.
"This research provides a clear welfare justification for giving NSAIDs to dairy cows with active digital dermatitis lesions, with significant milk yield benefits.”
Katherine Timms BVetMed(Hons) MRCVS, ruminant veterinary advisor at Ceva Animal Health said: “While it is recognised that some stages of digital dermatitis are painful, there has been little research to determine the value of including analgesia in the treatment of the condition.
“This study suggests that the use of Ketofen in the treatment of pain and lameness associated with active digital dermatitis lesions may be beneficial for animal welfare as it is associated with an improvement in mobility scores.”
Richard was nominated for his dedication to improving rabbit welfare, in particular for his work in getting a new vaccine in to the UK to protect all pet rabbits against an emerging deadly disease (RVHD2).
Richard qualified from Liverpool University in 1994, obtained his Certificate in Zoological Medicine in 2001 and his Diploma in Zoological Medicine in 2010, while he was an RWAF resident. Richard is also registered as a recognised RCVS Specialist in Zoo and Wildlife Medicine (one of only 30 in the world).
Rae Todd, CEO of the Rabbit Welfare Association & Fund said: "We're incredibly proud of Richard for all of his hard work and delighted that he's received recognition for his work. We all owe Richard a huge debt of gratitude for his commitment to the industry and for protecting all pet rabbits. So far, we estimate in the region of 70,000 rabbits have been vaccinated thanks to Richard."
Co-host of the awards, Matt Baker said: "I am truly humbled by the hard work and dedication of individuals and organisations who are passionate about improving animal welfare and would like to congratulate both the finalists and the award winners who are making a real difference to the lives of animals both in the UK and abroad."
Cuneyt Seckin, managing director of Ceva Animal Health, added: "The Ceva Animal Welfare Awards go from strength to strength, both in terms of the number and quality of entries that we receive during the nomination process and the dedication, commitment and enthusiasm of the finalists and winners who often go above and beyond the call of duty in the name of animal welfare."
Other winners this year included:
Welfare Nurse of the Year Award in association with Agria Pet InsuranceAdina Valentine, Blue Cross Animal Hospital in Grimsby
Charity Team of the Year supported by PDSAThe Dog Breeding Reform Group
Charitable Contribution of the Year supported by Blue Cross Helen Whiteside, Canine Research Associate at Guide Dogs
Farm Animal Welfare Award supported by R.A.B.I. and NADISThe University of Nottingham Dairy Herd Health Group
International Cat Care Welfare of the Year AwardMaria Pinto Teixeira from Animals de Rua (AdR) in Portugal
A sign up section where Official Veterinarians (OVs) can register to continue providing bTB testing with aspiring Delivery Partner Xperior Farm Health under AHVLA's Veterinary Delivery Partnership programme has been added to Xperior's website (www.xperiorfarmhealth.co.uk/vets/).
Xperior Farm Health is the joint venture between Eville & Jones and Westpoint Veterinary Group that is one of the declared bidders for appointment by AHVLA as a Delivery Partner. Veterinary Director Phil Elkins said: "If appointed, we are fully committed to maintaining sub-contractor OV involvement."
As alternatives to website sign up, OVs can also do so by email (phil.elkins@xperiorfarmhealth.co.uk) or post using either a printed form that was mailed recently to more than 1,000 farm vets or by writing to Mr Elkins at Century House, Thorpe Park, Leeds LS15 8ZB.
To give experienced OVs an opportunity to influence the Delivery Partner bid, Xperior have also extended their online survey (https://www.surveymonkey.com/s/PQFSWZN) until the end of July.
Phil added: "If appointed, our commitment is to provide an exemplary standard of accurate and trustworthy on-farm animal health testing services, where possible using subcontracted practices. These will be farmer friendly, provide an ongoing source of work and revenue to subcontractor Official Veterinarians, and represent excellent value for money to the taxpayer."